Antibody Targeted Amanitin Conjugates (ATACs) Overcome Resistance Mechanisms to Establish New Treatment Options for Difficult to Treat Cancers
Time: 9:20 am
day: Day Two
• ATACs represent a new class of ADCs using the payload Amanitin, introducing a novel mode of action (inhibition of RNA
polymerase II) into oncology therapy.
• The unique MoA facilitates killing of dormant tumor cells (CSCs, TICs) and offers new treatment options for difficult to treat
cancers and high-risk patients.
• HDP-101 is Heidelberg Pharma’s lead ATAC candidate directed against BCMA is entering Phase I clinical trials in relapsed
refractory multiple myeloma patients.